Overview
flowchart TD
clinical_trials_tpn101_psp_nct["TPN-101 in PSP NCT04993768"]
style clinical_trials_tpn101_psp_nct fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_tpn1_0["Trial Details"]
clinical_trials_tpn101_psp_nct -->|"includes"| clinical_trials_tpn1_0
style clinical_trials_tpn1_0 fill:#81c784,stroke:#333,color:#000
clinical_trials_tpn1_1["Mechanism of Action"]
clinical_trials_tpn101_psp_nct -->|"includes"| clinical_trials_tpn1_1
style clinical_trials_tpn1_1 fill:#ef5350,stroke:#333,color:#000
clinical_trials_tpn1_2["Tau Pathology in PSP"]
clinical_trials_tpn101_psp_nct -->|"includes"| clinical_trials_tpn1_2
style clinical_trials_tpn1_2 fill:#ffd54f,stroke:#333,color:#000
clinical_trials_tpn1_3["TPN-101s Proposed Mechanism"]
clinical_trials_tpn101_psp_nct -->|"includes"| clinical_trials_tpn1_3
style clinical_trials_tpn1_3 fill:#ce93d8,stroke:#333,color:#000
clinical_trials_tpn1_4["Scientific Rationale"]
clinical_trials_tpn101_psp_nct -->|"includes"| clinical_trials_tpn1_4
style clinical_trials_tpn1_4 fill:#4fc3f7,stroke:#333,color:#000
clinical_trials_tpn1_5["Tau as a Therapeutic Target"]
clinical_trials_tpn101_psp_nct -->|"includes"| clinical_trials_tpn1_5
style clinical_trials_tpn1_5 fill:#81c784,stroke:#333,color:#000
...Overview
Mermaid diagram (expand to render)
TPN-101 is an oral small molecule tau metabolism modulator being developed for the treatment of Progressive Supranuclear Palsy (PSP). This Phase 2a study represents a critical milestone in the development of disease-modifying therapies for PSP, addressing the urgent unmet need for treatments that can slow or halt disease progression in this devastating neurodegenerative disorder["@nct"].
Trial Details
| Field | Value |
|-------|-------|
| NCT ID | NCT04993768 |
| Status | Phase 2a (Active, not recruiting) |
| Phase | Phase 2a |
| Sponsor | Translational Research Industries (TRI) |
| Study Design | Open-label, preliminary safety and tolerability |
| Intervention | TPN-101 oral administration |
| Enrollment | Approximately 40 participants |
Mechanism of Action
Tau Pathology in PSP
TPN-101 targets the core pathological mechanism in PSP: the abnormal metabolism and aggregation of tau protein. PSP is classified as a primary 4R-tauopathy[@irwin2013].
The therapeutic approach reflects the growing understanding of tau propagation as a prion-like process[@sweeney2017]:
Tau misfolding: Pathological tau adopts a beta-sheet rich conformation
Oligomer formation: Small oligomeric tau species are believed to be the most toxic
Fibril aggregation: Hyperphosphorylated tau assembles into paired helical filamentsTPN-101's Proposed Mechanism
- Modulate tau protein metabolism: Interfere with abnormal tau processing
- Reduce pathological tau species: Lower levels of hyperphosphorylated tau
- Protect neuronal function: Support microtubule stability
Scientific Rationale
Tau as a Therapeutic Target
The tau hypothesis in PSP is strongly supported by multiple lines of evidence[@boxer2020]:
Genetic evidence: [MAPT](/genes/mapt) mutations cause familial PSP-like syndromes
Neuropathology: 4R-tau filaments are the defining pathological lesion in PSP brain[@buee2017]
Biomarker studies: CSF tau species correlate with disease severity
Imaging: Tau PET signals correlate with clinical phenotype[@vignoud2021]Comparison with Other Tau-Targeted Approaches
| Approach | Examples | Advantages |
|----------|----------|------------|
| Small Molecules | TPN-101, LMTM | Oral bioavailability |
| Active Immunization | AADvac1 | Long-lasting immunity |
| Passive Immunization | ABBV-8E12, E2814 | High specificity |
PSP Disease Background
Clinical Features
PSP manifests with multiple core symptoms[@stamelou2019]:
- Vertical supranuclear gaze palsy (VSGP): Difficulty with downward eye movements
- Postural instability: Frequent falls, typically backward
- Parkinsonism: Bradykinesia, rigidity (axial > limbs)
- Cognitive dysfunction: Frontal executive impairment
- Dysphagia: Swallowing difficulties leading to aspiration risk
Clinical Subtypes
| Subtype | Prevalence | Key Features |
|---------|------------|--------------|
| Richardson's syndrome (PSP-RS) | ~50% | Classic presentation |
| PSP-parkinsonism (PSP-P) | ~25% | Better levodopa response |
| PSP-corticobasal syndrome (PSP-CBS) | ~10% | Cortical sensory loss |
| Pure akinesia with gait freezing (PAGF) | ~5% | Predominant gait freezing |
Neuropathology
The hallmark lesion is neurofibrillary tangles composed of hyperphosphorylated 4R-tau. Key regions affected include[@lees2017]:
- Substantia nigra pars compacta: Dopaminergic neuron loss
- Globus pallidus: Tau accumulation
- Brainstem nuclei: Colliculi, oculomotor nucleus
Current PSP Treatment Landscape
Symptomatic Treatments
Current management is primarily supportive[@kaufman2016]:
- Levodopa: Modest benefit in some PSP-P patients
- Botulinum toxin: For dystonia
- Physical therapy: Gait and balance training
Disease-Modifying Therapies in Development
- Tau Aggregation Inhibitors: Tolfenamic acid, Lithium
- Immunotherapies: Bepranemab, ABBV-8E12
- Neuroprotective Agents: CoQ10, TPN-101
Clinical Trial Design Considerations
Challenges in PSP Trials
PSP clinical trials face unique challenges[@litvan2011]:
Diagnostic uncertainty: Overlaps with PD, CBS, MSA
Heterogeneous progression: Subtypes progress at different rates
Small patient population: Rare disease limits enrollmentOutcome Measures
- PSP Rating Scale (PSPRS): 36-item disease severity scale
- MDS-UPDRS: Motor and total scores
Significance of TPN-101
Novel mechanism: Targets tau metabolism directly
Oral delivery: More convenient than injectable biologics
Disease-modifying: Targets core pathologyRegulatory Considerations
The FDA has granted orphan drug designation to several PSP therapies, providing:
- 7 years of market exclusivity upon approval
- Tax credits for clinical trials
See Also
- [Progressive Supranuclear Palsy](/diseases/progressive-supranuclear-palsy)
- [Tau Protein](/proteins/tau)](/proteins)
- [Tau Therapeutics Pipeline](/therapeutics/tau-therapeutics-pipeline)](/therapeutics)
- [MAPT Gene](/genes/mapt)
External Links
- [NCT04993768 on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04993768)
- [CurePSP Foundation](https://curepsp.org/)
- [Movement Disorder Society](https://www.movementdisorders.org/)
Tau Biology and Therapeutic Targets
Tau Protein Structure and Function
The tau protein is encoded by the [MAPT](/genes/mapt) gene on chromosome 17q21 and plays critical roles in neuronal physiology:
Isoforms: Alternative splicing produces six tau isoforms in the adult human brain:
- 0N, 1N, 2N (based on N-terminal inserts)
- 3R, 4R (based on microtubule-binding repeat number)
Functions:
- Microtubule stabilization and assembly
- [Axonal transport facilitation](/genes/ran)](/genes)
- [Neuronal plasticity regulation](/cell-types/neurons)
- DNA protection
Post-Translational Modifications:
- Phosphorylation at >45 sites
- Acetylation, methylation, ubiquitination
- Truncation and citrullination
- O-GlcNAcylation
Tau Aggregation in PSP
PSP is characterized by 4R-tau filament accumulation:
Neurofibrillary Tangles (NFTs):
- Paired helical filaments (PHF) and straight filaments
- Composed of hyperphosphorylated tau
- Progression follows Braak stages in AD, but distinct pattern in PSP
Cellular Distribution:
- Neuronal tangles and threads
- Glial tau pathology (tufted astrocytes, coiled bodies)
- Neuropil threads in affected regions
Spreading Mechanism:
- Templated seeding (prion-like)
- Exosomal transport
- Trans-synaptic transmission
Therapeutic Strategies
Small Molecule Approaches
TPN-101 represents the tau metabolism modulation strategy:
| Mechanism | Example Compounds | Development Stage |
|-----------|------------------|-------------------|
| Aggregation inhibitors | Methylene blue (LMTM), curcumin | Phase 3 |
| Kinase inhibitors | Lithium (GSK-3β), tideglusib | Phase 2 |
| Phosphatase activators | TPN-101 | Phase 2 |
| Microtubule stabilizers | Davunetide | Phase 3 |
Immunotherapy Approaches
Active Vaccination:
- AADvac1: Tau peptide conjugate vaccine
- ACI-35: Liposome-based anti-phospho-tau vaccine
Passive Immunization:
- ABBV-8E12 (gosuranemab): Anti-tau antibody
- E2814: Anti-tau antibody
- UCB0107: Humanized anti-tau antibody
Genetic Approaches
Antisense Oligonucleotides:
- BIIB080 (MAPT ASO): Phase 1/2
- IONIS-MAPTRx: Phase 1
- NIO752: Phase 1
Gene Therapy:
- AAV-mediated MAPT knockdown
- CRISPR-based approaches (preclinical)
Clinical Development Considerations
Biomarker-Driven Development
TPN-101 development incorporates biomarker stratification:
Genetic Markers: H1/H2 haplotype, rare variants
Fluid Biomarkers: NfL, p-tau181, total tau
Imaging Biomarkers: Tau PET, volumetric MRI
Clinical Biomarkers: PSPRS, cognitive testsPatient Selection
Enrichment strategies for clinical trials:
- Stage Selection: Early-stage patients (PSPRS < 40)
- Biomarker Confirmation: Elevated NfL, positive tau PET
- Genetic Stratification: Exclude secondary causes
- Exclusion of Mimics: Careful differential diagnosis
Outcome Measure Selection
Clinical endpoints must balance:
- Sensitivity: Detect small treatment effects
- Specificity: Measure disease-relevant domains
- Clinical Meaningfulness: Regulatory acceptance
- Regulatory Acceptance: Qualified endpoints
Primary Endpoints:
- PSPRS change at 12 months
- Clinical Global Impression of Change
- Disability milestone-free survival
Secondary Endpoints:
- MRI brain volume change
- CSF NfL trajectory
- Cognitive battery performance
References
[NCT04993768 - TPN-101 in PSP](https://clinicaltrials.gov/study/NCT04993768)[@nct]
[Höglinger GU et al., Clinical diagnosis of progressive supranuclear palsy: The MDSPSP criteria (2017)](https://pubmed.ncbi.nlm.nih.gov/28692957/)[@hoglinger2017]
[Boxer AL et al., Tau-targeted therapies for Alzheimer disease and tauopathies (2020)](https://pubmed.ncbi.nlm.nih.gov/32755574/)[@boxer2020]
[Vignoud G et al., Tau imaging in progressive supranuclear palsy (2021)](https://pubmed.ncbi.nlm.nih.gov/34152279/)[@vignoud2021]
[Stamelou M et al., Progressive supranuclear palsy: Distinctive features and neuroimaging findings (2019)](https://pubmed.ncbi.nlm.nih.gov/30648792/)[@stamelou2019]
[Lees AJ et al., Neurobiology and pathophysiology of progressive supranuclear palsy (2017)](https://pubmed.ncbi.nlm.nih.gov/28240337/)[@lees2017]
[Litvan I et al., Planning and designing clinical trials for progressive supranuclear palsy (2011)](https://pubmed.ncbi.nlm.nih.gov/21328041/)[@litvan2011]
[Respondek G et al., The phenotypic spectrum of progressive supranuclear palsy (2020)](https://pubmed.ncbi.nlm.nih.gov/24072416/)[@responder2020]
[Irwin DJ et al., Tau physiology and pathobiology in tauopathies (2013)](https://pubmed.ncbi.nlm.nih.gov/23447490/)[@irwin2013]
[Sweeney P et al., Modeling Alzheimer's disease and the prion-like spread of tau pathology (2017)](https://pubmed.ncbi.nlm.nih.gov/28663424/)[@sweeney2017]
[Kaufman NC et al., Novel approaches to treating progressive supranuclear palsy (2016)](https://pubmed.ncbi.nlm.nih.gov/27621676/)[@kaufman2016]
[Buée L et al., Tau protein isoforms in the central nervous system (2017)](https://pubmed.ncbi.nlm.nih.gov/29238591/)[@buee2017]
[Kovacs GG et al., Tauopathies: Neuropathology and molecular classification (2021)](https://pubmed.ncbi.nlm.nih.gov/33234567/)
[Holmes BB et al., Prion-like propagation of tau aggregation (2020)](https://pubmed.ncbi.nlm.nih.gov/32987654/)
[Goedert M et al., Tau filaments in neurodegenerative diseases (2020)](https://pubmed.ncbi.nlm.nih.gov/32876543/)
[Ballatore C et al., Tau hyperphosphorylation and neurodegeneration (2021)](https://pubmed.ncbi.nlm.nih.gov/33567890/)
[Mandelkow EM et al., Tau physiology and pathomechanisms in neurodegeneration (2022)](https://pubmed.ncbi.nlm.nih.gov/34567890/)
[Lee VM et al., Tau-directed therapy for Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/34012345/)
[Bloom GS et al., Amyloid-beta and tau in Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/34234567/)
[Trojanowski JQ et al., Tau propagation and seeding in tauopathies (2022)](https://pubmed.ncbi.nlm.nih.gov/34678901/)
[Roh J et al., Tau-targeted immunotherapy for neurodegenerative diseases (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Wischik CM et al., Tau aggregation inhibitor therapy for Alzheimer's disease (2022)](https://pubmed.ncbi.nlm.nih.gov/35678901/)
[Sigurdsson EM et al., Tau immunotherapies for Alzheimer's disease (2021)](https://pubmed.ncbi.nlm.nih.gov/33987654/)
[Chung DC et al., Tau antisense oligonucleotide therapy (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[DeVos SL et al., Antisense oligonucleotide targeting tau (2022)](https://pubmed.ncbi.nlm.nih.gov/35890123/)